

synthetic chemokine protein so as to produce a synthetic chemokine in a substantially single oligomeric form.

91. (New) The method of claim 90, wherein said single oligomeric form is selected from the group consisting of monomer and dimer.

92. (New) The method of claim 90, wherein said synthetic chemokine protein is covalently modified with one or more polymers.

93. (New) The method of claim 90, wherein said synthesizing comprises chemical synthesis.

94. (New) The method of claim 93, wherein said chemical synthesis comprises the chemoselective ligation of non-overlapping peptide segments of said chemokine polypeptide derivative.

95. (New) The method of claim 94, wherein said chemoselective ligation is native - chemical ligation.

REMARKS

With this preliminary amendment, the specification has been amended to properly reflect the priority claim of the instant application. Claims 1-49 have been canceled and new claims 50-95 have been added, without prejudice or disclaimer of any previously claimed subject matter. Support for the amendment and new claims can be found throughout the specification and in originally filed claims, for example claims 1-49.

With respect to all amendments and cancelled claims, Applicants have not dedicated or abandoned any unclaimed subject matter. Applicants expressly reserve the right to pursue prosecution of any presently excluded subject matter or claim embodiments in one or more future continuation and/or divisional application(s).


Applicants respectfully request entry of this submission and believe that the present application is now in condition for allowance. The Examiner is encouraged to call the undersigned to discuss any issues related to the prosecution of the instant application.

No additional fees are believed due for this submission. However, if a fee is due, the Commissioner is hereby authorized to charge payment of any fees associated with this communication, to Applicant's Deposit Account No. 010535 referencing Docket No. 0960-UTL-GY. Additionally, the Commissioner is hereby authorized to charge payment or credit overpayment of any fees during the pendency of this application to Applicant's Deposit Account No. 010535.

Respectfully submitted,

AMYLIN PHARMACEUTICALS, INC.

Dated: September 18, 2006

By: 
Dianne Rees, Ph.D.
Registration No. 45,281

AMYLIN PHARMACEUTICALS, INC.
9360 Town Centre Drive
San Diego, CA 92121
Telephone: 858.552.2200
Facsimile: 858.552.1936